Company intelligence / Profile preview
Aida Pharmaceuticals
Hangzhou, Zhejiang, Chinabloomberg.com ↗
- Ownership
- Private
- Employees
- ~450
- Development stage
- Other
01
Overview
Aida Pharmaceuticals develops and markets antibiotics, cardiovascular drugs, and anti-cancer therapies in China. Its lead antibiotic etimicin sulfate is marketed commercially. The company’s biopharmaceutical candidate rh-Apo2L has completed Phase I trials with plans for further clinical development in oncology. Doxifluridine injection was in Phase IIa trials for advanced breast and gastric cancers but the trial status was suspended as of early 2025.
- Therapeutic areas
- Infectious DiseasesCardiovascularOncology
- Modalities
- Small moleculeBiologicRecombinant proteinAntibiotic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aida Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aida Pharmaceuticals.